| For: | Ma HN, Cao KS, Liu YM, Chen C, Zhang H, Tang FS. Tenofovir amibufenamide: A potential alternative for chronic hepatitis B treatment. World J Gastroenterol 2025; 31(10): 102580 [PMID: 40093664 DOI: 10.3748/wjg.v31.i10.102580] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v31/i10/102580.htm |
| Number | Citing Articles |
| 1 |
Zhi-Hao Zeng, Jin-Qing Liu, Min Zhang, Cai-Liang Qiu, Zhen-Yu Xu. Tenofovir amibufenamide in chronic hepatitis B: Lipid changes and 144-week safety with tenofovir disoproxil fumarate-to-tenofovir amibufenamide switch. World Journal of Gastroenterology 2025; 31(26): 109285 doi: 10.3748/wjg.v31.i26.109285
Abstract(356) |
Core Tip(334) |
Full Article(HTML)(2057)
|
Full Article (PDF)-1884K(180)
|
Full Article with Cover (PDF)-2247K(117)
|
Full Article (XML)-95K(88)
|
Audio-238K(33)
|
Peer-Review Report-331K(96)
|
Answering Reviewers-565K(93)
|
Supplementary Material-101K(84)
|
Times Cited (4)
|
Total Visits (6098)
|
Open
|
| 2 |
Aaminat Qureshi. Assessment of the inhibitory potential of tenofovir ester conjugates against α-glucosidase activity using in-vitro and in-silico methods. Pakistan Journal of Pharmaceutical Sciences 2027; doi: 10.36721/PJPS/2026.40.15688.1
|